title: Comparison of reactogenicity and antigenicity of M37 rotavirus vaccine and rhesus-rotavirus-based quadrivalent vaccine.
abstract: 90 Venezuelan infants aged 10-20 weeks were randomly allocated to four groups which received one of the following: the M37 vaccine (1 x 10(4) pfu [plaque-forming units]); quadrivalent rotavirus vaccine (1 x 10(4) pfu each of serotype 3 rhesus rotavirus [RRV] and human rotavirus-RRV reassortants of serotypes 1, 2, and 4); balanced quadrivalent vaccine consisting of 1 x 10(4) pfu of serotype 1 and 3 components but 5 x 10(4) pfu of serotype 2 and 4 components; or placebo. The frequencies of transient febrile responses in these four groups were 20%, 27%, 30%, and 9%. 50% of 22 infants tested who received M37 vaccine showed a serum rotavirus IgA antibody response, compared with 74% of the 23 quadrivalent and 86% of the 22 balanced-quadrivalent recipients. 64% of the M37 recipients showed a neutralising antibody response to M37; 27% showed such responses to human serotype 1 Wa strain and 27% to serotype 4 neonatal strain ST3. 17-39% of the quadrivalent recipients and 27-41% of the balanced-quadrivalent recipients showed neutralising antibody responses to serotypes 1-4. 70-73% of the quadrivalent and balanced quadrivalent groups also showed neutralising antibody responses to RRV.
authors.affiliation: Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892.
authors.forename: J
authors.initials: J
authors.lastname: Flores
authors.forename: I
authors.initials: I
authors.lastname: Perez-Schael
authors.forename: M
authors.initials: M
authors.lastname: Blanco
authors.forename: L
authors.initials: L
authors.lastname: White
authors.forename: D
authors.initials: D
authors.lastname: Garcia
authors.forename: M
authors.initials: M
authors.lastname: Vilar
authors.forename: W
authors.initials: W
authors.lastname: Cunto
authors.forename: R
authors.initials: R
authors.lastname: Gonzalez
authors.forename: C
authors.initials: C
authors.lastname: Urbina
authors.forename: J
authors.initials: J
authors.lastname: Boher
mesh_terms: D000914:Antibodies, Viral / Q000096:biosynthesis; D003429:Cross Reactions; D004311:Double-Blind Method; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007070:Immunoglobulin A / Q000096:biosynthesis; D007223:Infant; D011897:Random Allocation; D012401:Rotavirus / Q000276:immunology*; D012400:Rotavirus Infections / Q000517:prevention & control*; D014765:Viral Vaccines / Q000276:immunology*
chemical_list: D000914:Antibodies, Viral; D007070:Immunoglobulin A; D014765:Viral Vaccines